A sweet surprise for HIV broadly neutralizing antibodies.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 23135511.
- Also identified by DOI 10.1038/nm.2993.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The production of cross-reactive neutralizing antibodies is the ultimate goal in HIV vaccine development, but no immunogen other than HIV itself has been able to elicit this type of humoral immunity. In natural HIV infections, these antibodies take several years to develop. A new study sheds light on what may be causing this delay in neutralizing antibody development (pages 1688-1692).
Medical subject headings
- Antibodies, Neutralizing
- Epitopes
- HIV
- HIV-1
- Polysaccharides